Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

19 Oct 2024

Real-Life Fungi in Fiction: The Origins of ‘Bliss’ in The Penguin

Derived from the real-life Bleeding Tooth Fungus (Hydnellum peckii), Bliss is portrayed as a euphoric stimulant, manufactured in underground labs. While the fungus’ crimson fluid looks sinister, it isn't psychoactive....

By Microdose NewsDesk

Breaking News

10 Sep 2024

Mindstate Design Labs AI-Designed Trial Gets FDA Approval

Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. This approval is a clinical validation...

By Microdose NewsDesk
cybin deal

Breaking News

6 Sep 2024

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics

Psyence Biomed announces acquisition Clairvoyant Therapeutics and its Phase 2b trial...

By Microdose NewsDesk

Science

30 May 2024

Interview with Terran’s CEO Sam Clark on Terran’s pipeline, including “TerXT” for schizophrenia, a new competitor to Karuna’s KarXT

We sat down with Sam Clark, CEO of Terran Biosciences, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. This new treatment is designed to...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

26 Feb 2024

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2A Take-Home Microdosing Trial

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression...

By Microdose NewsDesk

Industry

20 Dec 2023

Terran Biosciences Receives FDA Clearance for MRI Scan Technology

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI...

By Microdose NewsDesk
news

Don’t Miss

18 Dec 2023

News You Might Have Missed: Dec 18th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Science

14 Dec 2023

MindMed Announces Positive Results from Phase 2b Anxiety Trial

Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4....

By Microdose NewsDesk
maps

Breaking News

12 Dec 2023

Breaking News: MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy

Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy....

By Microdose NewsDesk

Follow us on social

Latest News

Medical Psilocybin Act

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.